Clinical Trials Sponsored by IQVIA Biotech

Total 1904 results

Synlogic
IQVIA Biotech

Recruiting

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects

Lymphoma | Metastatic Solid Neoplasm

United States
Blueberry Therapeutics
IQVIA Biotech

Completed

A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail

Fungal Infection | Distal Subungual Onychomycosis | Fungus, Nail

Poland, Germany, Czechia
Inozyme Pharma
IQVIA Biotech

Active, not recruiting

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

Pseudoxanthoma Elasticum | Generalized Arterial Calcification of Infancy | ATP-Binding Cassette Subfamily C Member 6 Deficiency

United States, United Kingdom
Mersana Therapeutics
IQVIA Biotech

Terminated

First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Ovarian Cancer | Nonsmall Cell Lung Cancer

United States
Keros Therapeutics, Inc.
IQVIA Biotech

Recruiting

Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis

Myelofibrosis

Australia
Delcath Systems Inc.
IQVIA Biotech

Completed

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma (FOCUS)

Melanoma, Ocular

United States, Spain, Italy, Germany, United Kingdom, Switzerland, Belgium, Austria, France
BioXcel Therapeutics Inc
IQVIA Biotech

Withdrawn

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, Pancreatic

United States
Celyad Oncology SA
IQVIA Biotech

Completed

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 (DEPLETHINK)

AML | MDS

United States, Belgium
Milestone Pharmaceuticals Inc.
IQVIA Biotech

Completed

Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303

Paroxysmal Supraventricular Tachycardia

United States, Argentina, Brazil, Canada, Colombia
Noveome Biotherapeutics, formerly Stemnion
IQVIA Biotech

Terminated

ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects

Persistent Corneal Epithelial Defect

United States
Noveome Biotherapeutics, formerly Stemnion
IQVIA Biotech

Completed

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

Cytokine Release Syndrome

United States
Mersana Therapeutics
IQVIA Biotech; PSI CRO

Terminated

Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer (UPGRADE)

Platinum-sensitive Ovarian Cancer (UPGRADE-A)

United States
F2G Biotech GmbH
Iqvia Pty Ltd

Recruiting

Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options (FORMULA-OLS)

Invasive Fungal Infections

United States, Netherlands, Israel, Spain, Korea, Republic of, Belgium, Australia, Germany, France, Brazil, Poland, Egypt, Russian Federation, Thailand, Turkey, United Kingdom, Vietnam
Mersana Therapeutics
IQVIA Biotech; PSI CRO

Recruiting

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Platinum Resistant Ovarian Cancer | Non Small Cell Lung Cancer Metastatic

United States, Spain, United Kingdom, Australia, France, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, Hungary, Italy, Lithuania, New Zealand, Norway, Poland, Sweden
Milestone Pharmaceuticals Inc.
Medpace, Inc.; IQVIA Biotech

Completed

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxymal Supraventricular Tachycardia (PSVT). NODE 301 [Part 1 and Part 2 (RAPID Study)]

Paroxysmal Supraventricular Tachycardia

United States, Spain, Canada, Belgium, France, Netherlands, Hungary, Poland, Germany
Perception Neuroscience
Precision For Medicine; IQVIA Biotech

Completed

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

Treatment Resistant Depression

United States, Germany, Poland
F2G Biotech GmbH
Iqvia Pty Ltd; Shionogi

Recruiting

Olorofim Aspergillus Infection Study (OASIS)

Invasive Aspergillosis

United States, Taiwan, Belgium, Spain, Italy, Turkey, New Zealand, China, Canada, Netherlands, Australia, Brazil, Singapore, Israel, France, Thailand, Germany, Japan, Korea, Republic of, United Kingdom
Lifetech Scientific (Shenzhen) Co., Ltd.
IQVIA Biotech

Active, not recruiting

Lifetech LAmbre™ Left Atrial Appendage (LAA) Closure System Post-Market Clinical Follow-up Study (LISA)

Atrial Fibrillation

China, Denmark, Germany, Ireland, Italy, Poland, Spain, Sweden, Thailand
Dermavant Sciences GmbH
IQVIA Biotech

Completed

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

Plaque Psoriasis

United States, Canada
Dermavant Sciences GmbH
IQVIA Biotech

Completed

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

Plaque Psoriasis

United States, Canada
Dermavant Sciences GmbH
IQVIA Biotech

Completed

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

Plaque Psoriasis

United States, Canada
Aboca Spa Societa' Agricola
IQVIA RDS; IQVIA Solutions

Recruiting

Oral Administration of Actitan-F in Paediatric Diarrhoea

Chronic Diarrhoea of Infants and/or Young Children

Italy
Aboca Spa Societa' Agricola
IQVIA RDS; IQVIA Solutions

Completed

Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome.

Irritable Bowel Syndrome

Italy, Germany
GlaxoSmithKline
IQVIA, USA

Active, not recruiting

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Chickenpox

Taiwan, Poland, United States, Estonia, Puerto Rico, Mexico
Iqvia Pty Ltd

Completed

COVID-19 Active Research Experience (CARE)

COVID-19

United States, United Kingdom
Iqvia Pty Ltd

Terminated

Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid Tumours

Cancer - Solid Tumours

Australia
Bharat Biotech International Limited
Indian Council of Medical Research; Iqvia Pty Ltd

Active, not recruiting

An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers

Covid19 | SARS-CoV Infection

India
Theratocular Biotek Co.

Recruiting

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

Thailand
argenx
Iqvia Pty Ltd

Recruiting

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome (Rho plus)

Primary Sjögren's Syndrome

Belgium, Hungary, Poland
AstraZeneca
IQVIA RDS Inc.

Recruiting

Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China (CHIMES)

Lower Respiratory Tract Infection

China
AstraZeneca
Iqvia Pty Ltd

Recruiting

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus (Tulip SC)

Systemic Lupus Erythematosus

Germany, Hungary, Japan, Mexico, United States, Argentina, Bulgaria, Chile, Colombia, Peru, Poland, Spain, Ukraine, United Kingdom, Russian Federation
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)

SCLC | Breast | Ovarian | Gastric Cancers

United Kingdom, United States, Korea, Republic of, France, Netherlands, Israel, Switzerland
GlaxoSmithKline
Iqvia Pty Ltd

Terminated

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (contRAst 2)

Arthritis, Rheumatoid

United States, Australia, Germany, Japan, Korea, Republic of, Poland, Bulgaria, Estonia, Hungary, Mexico, Russian Federation, Spain, Thailand, Colombia, China, Argentina, United Kingdom, France
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (contRAst 3)

Arthritis, Rheumatoid

United States, Germany, Canada, Czechia, Poland, South Africa, Korea, Republic of, Spain, Japan, Argentina, Belgium, Hungary, United Kingdom, Italy, Lithuania
GlaxoSmithKline
Iqvia Pty Ltd

Active, not recruiting

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 6)

Multiple Myeloma

United States, Australia, Spain, United Kingdom, Canada
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
AbbVie
IQVIA, formerly Quintiles

Completed

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Advanced Parkinson's Disease

United Kingdom, Czechia, United States, Australia, Canada, Israel, New Zealand, Poland, Portugal, Russian Federation, Thailand
AstraZeneca
Iqvia Pty Ltd

Terminated

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease (HESTIA3)

Sickle Cell Disease

Italy, Spain, United Kingdom, Belgium, United States, India, South Africa, Brazil, Turkey, Egypt, Ghana, Greece, Kenya, Lebanon, Tanzania, Uganda
Prokidney
Iqvia Pty Ltd

Not yet recruiting

A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease

Chronic Kidney Diseases | Type 2 Diabetes Mellitus
GlaxoSmithKline
Iqvia Pty Ltd

Recruiting

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (NIMBLE)

Asthma

United States, Australia, Austria, Canada, Finland, France, Germany, Ireland, Italy, Japan, Netherlands, Norway, Poland, Puerto Rico, Slovenia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, Israel, Portugal
AstraZeneca
Iqvia Pty Ltd

Terminated

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) (ARROYO)

Chronic Spontaneous Urticaria

United States, Germany, Korea, Republic of, Spain, Bulgaria, Poland, Japan
GlaxoSmithKline
Iqvia Pty Ltd

Terminated

Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) (contRAst X)

Arthritis, Rheumatoid

United States, Germany, Japan, Korea, Republic of, Poland, Ukraine, Bulgaria, Canada, Czechia, Estonia, Hungary, Mexico, Russian Federation, South Africa, Spain, Malaysia, Thailand, China, Argentina, Belgium, India, United Kingdom, ... and more
argenx
Iqvia Pty Ltd

Active, not recruiting

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS (POTS)

Postural Orthostatic Tachycardia Syndrome

United States
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults (STORM CHASER)

COVID-19

United States, United Kingdom
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab (JUBILUS)

Respiratory Syncytial Virus Infections

Japan
argenx
Iqvia Pty Ltd

Recruiting

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS (POTS)

Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome

United States
GlaxoSmithKline
Iqvia Pty Ltd

Recruiting

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) (AGILE)

Asthma

United States, Australia, Canada, France, Germany, Italy, Japan, Poland, Spain, China, Czechia, Hungary, Taiwan, United Kingdom
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India

Respiratory Tract Infections | Otitis Media | Infections, Respiratory Tract

India
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (contRAst 1)

Arthritis, Rheumatoid

Hungary, Poland, Malaysia, Spain, China, Russian Federation, India, United Kingdom, Italy, Serbia
AstraZeneca
Iqvia Pty Ltd

Completed

Study of AZD1222 for the Prevention of COVID-19 in Japan

COVID-19

Japan

Clinical Trials Sponsored by IQVIA Biotech

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations